Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results 1 month ago [#item_full_content] Share this: Tenax Therapeutics Provides 2023 Business UpdateDateApril 12, 2023In relation tobiotech newsTenax Therapeutics Announces the Evaluation of Strategic AlternativesDateSeptember 15, 2022In relation tobiotech newsTenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)DateFebruary 1, 2023In relation tobiotech news
